Search results for "androgens"

showing 9 items of 79 documents

Serum androsterone conjugates differentiate between acne and hirsutism in hyperandrogenic women

1991

Objective To determine if among hyperandrogenic women acne may be differentiated from hirsutism by markers of peripheral androgen metabolism. Design Prospective outpatient study of 36 hyperandrogenic women and controls divided into groups based on the presence or absence of significant hirsutism and the presence or absence of moderate to severe acne. Serum levels of adrenal and ovarian derived androgens were elevated but similar in all patient groups. Interventions Measurement of serum androgens including metabolites of 5 α -reductase activity: 3 α -androstanediol glucuronide and sulfate and androsterone (A) glucuronide and sulfate. Results 3 α -androstanediol glucuronide and sulfate were e…

medicine.medical_specialtyAndrosteronebusiness.industrymedicine.drug_classHyperandrogenismObstetrics and Gynecologymedicine.diseaseAndrogenchemistry.chemical_compoundEndocrinologyReproductive MedicinechemistryInternal medicineMedicineSerum androgensbusinessGlucuronideAcnehirsutismAndrostanediol glucuronideFertility and Sterility
researchProduct

Anti-androgens for the treatment of hirsutism.

2002

Many alternatives exist for treating hirsutism. Based on an analysis of scientific literature and on the experiences of the author, the most common anti-androgen agents are discussed in this review. Androgen receptor blockers (cyproterone acetate, flutamide and spironolactone), 5 alpha-reductase inhibitors (finasteride) and androgen-suppressing agents (gonadotrophin-releasing hormone [GnRH] agonists, oestroprogestins, corticosteroids and insulin-sensitising agents) are evaluated and compared. The importance of diagnosis in choosing the most appropriate anti-androgen treatment is also discussed.

medicine.medical_specialtyCholestenone 5 alpha-ReductaseHirsutismAnti-Androgenurologic and male genital diseasesFlutamideGonadotropin-Releasing Hormonechemistry.chemical_compoundInternal medicineAndrogen Receptor AntagonistsMedicineHumansPharmacology (medical)Androgen Receptor AntagonistshirsutismPharmacologybusiness.industryCyproterone acetateAndrogen AntagonistsGeneral Medicinemedicine.diseaseAndrogen receptorEndocrinologyTreatment OutcomechemistrySpironolactoneFinasterideAndrogensFemalebusinessOxidoreductasesExpert opinion on investigational drugs
researchProduct

The effects of transdermal testosterone and oestrogen therapy on dry eye in postmenopausal women: a randomised, placebo-controlled, pilot study

2016

Aims Sex hormones could provide a future treatment avenue for dry eye post menopause. However, there are few well-controlled studies. This study investigates the impact of testosterone and oestrogen on dry eye symptoms and signs in postmenopausal women. Methods A randomised double-blind placebo-controlled pilot study was conducted involving 40 women with dry eye (age 63.9±5.1 years, 13.2±6.3 years post menopause). Ten women were assigned to each of four treatment groups: transdermal testosterone, oestradiol, testosterone/oestradiol combination and placebo. Assessment at baseline and after 8 weeks: ocular symptoms, tear osmolarity, tear stability, tear secretion, meibomian gland assessment, …

medicine.medical_specialtyTime Factorsmedicine.drug_classMeibomian glandPhysiologyPilot ProjectsAdministration CutaneousPlacebo03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compound0302 clinical medicineDehydroepiandrosterone sulfateDouble-Blind MethodInternal medicineHumansMedicineTestosteroneTear secretionRetrospective Studies030219 obstetrics & reproductive medicinebusiness.industryMeibomian GlandsEstrogensTestosterone (patch)Middle AgedAndrogeneye diseasesSensory SystemsPostmenopauseOphthalmologyTreatment Outcomemedicine.anatomical_structureEndocrinologychemistryTearsAndrogens030221 ophthalmology & optometryTearsDry Eye SyndromesFemalesense organsbusinessFollow-Up StudiesHormoneBritish Journal of Ophthalmology
researchProduct

Molecular Analysis of the Androgen Receptor Gene in 52 Patients with Complete or Partial Androgen Insensitivity Syndrome: A Collaborative Study

1992

In patients with androgen insensitivity syndrome (AIS), RFLP study of the androgen receptor gene made it possible to analyze whether deletions or mutations could be responsible for abnormalities in androgen responsiveness. We studied RFLPs of DNA from 25 46,XY patients with partial AIS (PAIS), defined as a concentration of androgen receptor in genital-skin fibroblasts less than 340 fmol/mg DNA, and DNA from 27 46,XY patients with complete AIS (CAIS) with no detectable androgen receptor site. DNA samples were digested with BamHI, EcoRI, HindIII and TaqI restriction enzymes and hybridized with three cDNA probes covering the three domains of the androgen receptor. When we had the maternal and …

medicine.medical_specialtyX Chromosomemedicine.drug_classEndocrinology Diabetes and MetabolismMolecular Sequence DataDeoxyribonuclease HindIIIBiologyurologic and male genital diseasesPolymerase Chain Reactionchemistry.chemical_compoundEndocrinologyInternal medicinemedicineHumansPartial androgen insensitivity syndromeGeneSex Chromosome AberrationsBase SequenceAndrogen Receptor GeneDNASyndromeMetribolonemedicine.diseaseAndrogenMolecular analysisEndocrinologychemistryReceptors AndrogenMutationAndrogensAndrogen insensitivity syndromeRestriction fragment length polymorphismPolymorphism Restriction Fragment LengthDNAHormone Research
researchProduct

DHEA, DHEAS and PCOS.

2014

Approximately 20-30% of PCOS women demonstrate excess adrenal precursor androgen (APA) production, primarily using DHEAS as a marker of APA in general and more specifically DHEA, synthesis. The role of APA excess in determining or causing PCOS is unclear, although observations in patients with inherited APA excess (e.g., patients with 21-hydroxylase deficient congenital classic or non-classic adrenal hyperplasia) demonstrate that APA excess can result in a PCOS-like phenotype. Inherited defects of the enzymes responsible for steroid biosynthesis, or defects in cortisol metabolism, account for only a very small fraction of women suffering from hyperandrogenism or APA excess. Rather, women wi…

medicine.medical_specialtyendocrine system diseasesmedicine.drug_classEndocrinology Diabetes and Metabolismmedicine.medical_treatmenteducationClinical BiochemistryPopulationSingle-nucleotide polymorphismSteroid biosynthesisBiochemistryBody Mass IndexEndocrinologyRisk FactorsInternal medicinemental disordersmedicinePrevalenceAnimalsHumanseducationMolecular Biologyeducation.field_of_studybusiness.industryDehydroepiandrosterone SulfateInsulinHyperandrogenismCell BiologyDehydroepiandrosteroneHyperplasiaAndrogenmedicine.diseaseObesityEndocrinologyPhenotypeCardiovascular DiseasesAndrogensMolecular MedicineFemaleSteroidsbusinessHyperandrogenismpsychological phenomena and processesPolycystic Ovary SyndromeThe Journal of steroid biochemistry and molecular biology
researchProduct

Relationships Between Biochemical Markers of Hyperandrogenism and Metabolic Parameters in Women with Polycystic Ovary Syndrome: A Systematic Review a…

2019

AbstractWhile several studies have documented an increased risk of metabolic disorders in patients with polycystic ovary syndrome (PCOS), associations between androgenic and metabolic parameters in these patients are unclear. We aimed to investigate the relationships between biochemical markers of hyperandrogenism (HA) and metabolic parameters in women with PCOS. In this systematic review and meta-analysis, a literature search was performed in the PubMed, Scopus, Google Scholar, ScienceDirect, and Web of Science from 2000 to 2018 for assessing androgenic and metabolic parameters in PCOS patients. To assess the relationships between androgenic and metabolic parameters, meta-regression analys…

medicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryBlood Pressure030209 endocrinology & metabolism030204 cardiovascular system & hematologyBiochemistryFerriman–Gallwey score03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyDehydroepiandrosterone sulfateInsulin resistanceInternal medicinemedicineHumansInsulinTestosteronebusiness.industryBiochemistry (medical)Metabolic disorderHyperandrogenismConfoundingGeneral Medicinemedicine.diseaseAndrogenPolycystic ovaryCholesterolEndocrinologychemistryAndrogensFemaleHyperandrogenismbusinessPolycystic Ovary SyndromeHormone and Metabolic Research
researchProduct

Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.

2004

Today, androgen deprivation therapy is a cornerstone of treatment for advanced prostate cancer, although it presents important complications such as osteoporosis. Neridronate, a relatively new bisphosphonate, is able to prevent bone loss in patients with prostate cancer during androgen ablation. Introduction: Androgen-deprivation therapy (ADT) is a cornerstone of treatment for advanced prostate cancer. This therapy has iatrogenic complications, such as osteoporosis. The aim of our study was to evaluate the efficacy of neridronate, a relatively new bisphosphonate, to prevent bone loss during androgen ablation. Materials and Methods: Forty-eight osteoporotic patients with prostate cancer, tre…

musculoskeletal diseasesMalemedicine.medical_specialtyDeoxypyridinolineTime FactorsBicalutamideAntineoplastic Agents HormonalEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrologyBone and BonesAndrogen deprivation therapychemistry.chemical_compoundProstate cancerAbsorptiometry PhotonBone DensityMedicineNeridronic acidHumansOrthopedics and Sports MedicineAmino AcidsAgedCholecalciferolTriptorelin PamoateDiphosphonatesbusiness.industryProstatic NeoplasmsAndrogen AntagonistsBisphosphonatemedicine.diseaseAlkaline PhosphataseAndrogen deprivation therapy; Bisphosphonates; Neridronate; Osteoporosis; Prostate cancer; Absorptiometry Photon; Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Androgens; Antineoplastic Agents Hormonal; Bone Density; Bone and Bones; Calcium; Cholecalciferol; Diphosphonates; Humans; Male; Osteoporosis; Prostatic Neoplasms; Time Factors; Triptorelin Pamoate; SurgerySurgerychemistryAndrogensOsteoporosisCalciumbusinessCholecalciferolmedicine.drugJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
researchProduct

Diet to Reduce the Metabolic Syndrome Associated with Menopause. The Logic for Olive Oil

2020

The rates of metabolic syndrome are increasing in parallel with the increasing prevalence of obesity, primarily due to its concomitant insulin resistance. This is particularly concerning for women, as the years around menopause are accompanied by an increase in visceral obesity, a strong determinant of insulin resistance. A fall in estrogens and increase in the androgen/estrogen ratio is attributed a determining role in this process, which has been confirmed in other physiological models, such as polycystic ovary syndrome. A healthy lifestyle, with special emphasis on nutrition, has been recommended as a first-line strategy in consensuses and guidelines. A consistent body of evidence has ac…

obesityMediterranean dietmedicine.drug_classmenopausePhysiologylcsh:TX341-641030209 endocrinology & metabolismReviewDisease030204 cardiovascular system & hematologyDiet Mediterraneanmetabolic syndromeHealthy Aging03 medical and health sciences0302 clinical medicineInsulin resistanceHumansMedicineNutritional Physiological PhenomenaHealthy LifestyleAgedNutrition and Dieteticsbusiness.industryEstrogensMiddle Agedolive oilmedicine.diseasePolycystic ovaryObesityMenopauseEstrogenObesity AbdominalAndrogensFemalewomenDiet HealthyInsulin ResistanceMetabolic syndromehealthy ageingbusinesslcsh:Nutrition. Foods and food supplyFood ScienceNutrients
researchProduct

Sex steroid hormone receptors, their ligands, and nuclear and non-nuclear pathways

2015

The ability of a cell to respond to a particular hormone depends on the presence of specific receptors for those hormones. Once the hormone has bound to its receptor, and following structural and biochemical modifications to the receptor, it separates from cytoplasmic chaperone proteins, thereby exposing the nuclear localization sequences that result in the activation of the receptor and initiation of the biological actions of the hormone on the target cell. In addition, recent work has demonstrated new pathways of steroid signaling through orphan and cell surface receptors that contribute to more rapid, “non-nuclear” or non-transcriptional effects of steroid hormones, often involving G-pro…

orphan receptorreceptorreceptorsandrogenBiologyprogesteronegenomic pathwaySettore BIO/10 - Biochimicaestrogensex steroid hormoneReceptorlcsh:Science (General)Orphan receptorHormone response elementsex steroid hormones; receptors; estrogens; androgens; progesterone; genomic pathway; non-genomic pathway; orphan receptorandrogensSex hormone receptornon-genomic pathwayBiochemistryNuclear receptorSex steroidHormone receptorsex steroid hormonesEstrogen-related receptor gammaestrogenslcsh:Q1-390AIMS Molecular Science
researchProduct